← Back to Search

Exercise for Obesity

Led By Robert C Hickner, PhD
Research Sponsored by Florida State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women will be on combined estrogen/progestin hormonal contraceptive therapy (oral pill, transdermal patch or vaginal ring)
Women will be premenopausal
Must not have
Individuals with chronic infections, paralysis due to stroke, advanced Parkinson's Disease, severe rheumatoid arthritis or other serious orthopedic problems that would prevent performance of the exercise training tasks
Individuals with ECG evidence of serious arrhythmias and/or acute myocardial ischemia reflected in ST-segment depression of 1 mm or greater at rest or during exercise
Screening 3 weeks
Treatment Varies
Follow Up change from week 0 to week 8
Awards & highlights


This trial will study the effects of aerobic interval training on microvascular endothelial function in obese individuals.

Who is the study for?
This trial is for premenopausal women who are obese, sedentary, and have been weight stable for the last 6 months. They must meet at least three criteria of Metabolic Syndrome such as a large waist size or high blood pressure. Participants should not be taking certain medications or supplements that affect circulation or oxidative stress.Check my eligibility
What is being tested?
The study tests how an 8-week aerobic interval exercise program affects obesity-related endothelial dysfunction by reducing oxidative stress in muscles. It explores the role of NADPH oxidase activity and mitochondrial ROS in improving vascular health through exercise.See study design
What are the potential side effects?
Since this trial involves exercise as an intervention, potential side effects may include muscle soreness, fatigue, joint pain, and risk of injury related to physical activity. However, these are common reactions to new exercise routines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am using a combined hormonal contraceptive method.
I am a woman and have not gone through menopause.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I do not have conditions like severe arthritis, Parkinson's, or paralysis that would stop me from doing exercise tasks.
My heart tests show serious irregular beats or signs of not enough blood flow.
I have heart failure, chest pain, or circulation problems in my limbs.
I have diabetes with a fasting blood sugar over 125 mg/dL.
I am a pre-menopausal woman not pregnant or breastfeeding, with regular periods over the last year.
I am currently taking NSAIDs or SSRIs.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 0 to week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 0 to week 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reactive oxygen species (ROS)
Secondary outcome measures
Muscle blood flow

Trial Design

1Treatment groups
Experimental Treatment
Group I: Exercise trainingExperimental Treatment1 Intervention
Eight weeks of interval exercise training
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Find a Location

Who is running the clinical trial?

Florida State UniversityLead Sponsor
204 Previous Clinical Trials
32,337 Total Patients Enrolled
16 Trials studying Obesity
1,329 Patients Enrolled for Obesity
Robert C Hickner, PhDPrincipal InvestigatorFlorida State University
1 Previous Clinical Trials
120 Total Patients Enrolled
1 Trials studying Obesity
120 Patients Enrolled for Obesity

Media Library

Exercise Clinical Trial Eligibility Overview. Trial Name: NCT04087655 — N/A
Obesity Research Study Groups: Exercise training
Obesity Clinical Trial 2023: Exercise Highlights & Side Effects. Trial Name: NCT04087655 — N/A
Exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT04087655 — N/A
~4 spots leftby Jul 2025